Adult patients (> 18 years of age) undergoing palliative care (defined by the WHO as active, comprehensive care given to patients whose condition does not respond to curative treatment) of their disease, able to communicate, and with a functional central venous line with reflux, presenting spontaneous pain with a numerical scale greater than 3 or paracetamol as part of their usual treatment.
Conditions
Brief summary
- Measurement of paracetamolemia to determine AUC0-t, AUC0-, Cmax , Vd and t1/2 for each mode of administration for the same patient, and generation of pharmacokinetic curves.
Detailed description
- Pain assessment using a digital scale, - Skin monitoring and tolerance assessment throughout administration and protocol completion (D0 to D30), - Safety criterion: systematic collection of adverse events of any grade (CTCAE scale) from the signing of consent to D30 (minimum follow-up period for drug research).
Interventions
DRUGsolution pour perfusion
Sponsors
Centre Hospitalier Universitaire De Caen Normandie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Measurement of paracetamolemia to determine AUC0-t, AUC0-, Cmax , Vd and t1/2 for each mode of administration for the same patient, and generation of pharmacokinetic curves. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Pain assessment using a digital scale, - Skin monitoring and tolerance assessment throughout administration and protocol completion (D0 to D30), - Safety criterion: systematic collection of adverse events of any grade (CTCAE scale) from the signing of consent to D30 (minimum follow-up period for drug research). | — |
Countries
France
Outcome results
None listed